Immuno-MALDI-MS for Accurate Quantitation of Targeted Peptides from Volume-Restricted Samples

Sobsey, Constance A.; Froehlich, Bjoern C.; Batist, Gerald; Borchers, Christoph H.

doi:10.1007/978-1-0716-2409-8_13

Cited by 1 publication

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…New workflows are being developed for working with lowlevel 44,49,109−111 and low-volume samples. 29,112 Network analysis continues to inform studies on disease-related pathways. 113−116 The microbiome, now considered as an "organ" in its own right, 117 plays key roles in multiple pathologies.…”

Section: ■ Pathology Pillarmentioning

confidence: 99%

See 1 more Smart Citation

The 2023 Report on the Proteome from the HUPO Human Proteome Project

Omenn,

Lane,

Overall

et al. 2024

J. Proteome Res.

View full text Add to dashboard Cite

Since 2010, the Human Proteome Project (HPP), the flagship initiative of the Human Proteome Organization (HUPO), has pursued two goals: (1) to credibly identify the protein parts list and (2) to make proteomics an integral part of multiomics studies of human health and disease. The HPP relies on international collaboration, data sharing, standardized reanalysis of MS data sets by PeptideAtlas and MassIVE-KB using HPP Guidelines for quality assurance, integration and curation of MS and non-MS protein data by neXtProt, plus extensive use of antibody profiling carried out by the Human Protein Atlas. According to the neXtProt release 2023-04-18, protein expression has now been credibly detected (PE1) for 18,397 of the 19,778 neXtProt predicted proteins coded in the human genome (93%). Of these PE1 proteins, 17,453 were detected with mass spectrometry (MS) in accordance with HPP Guidelines and 944 by a variety of non-MS methods. The number of neXtProt PE2, PE3, and PE4 missing proteins now stands at 1381. Achieving the unambiguous identification of 93% of predicted proteins encoded from across all chromosomes represents remarkable experimental progress on the Human Proteome parts list. Meanwhile, there are several categories of predicted proteins that have proved resistant to detection regardless of protein-based methods used. Additionally there are some PE1–4 proteins that probably should be reclassified to PE5, specifically 21 LINC entries and ∼30 HERV entries; these are being addressed in the present year. Applying proteomics in a wide array of biological and clinical studies ensures integration with other omics platforms as reported by the Biology and Disease-driven HPP teams and the antibody and pathology resource pillars. Current progress has positioned the HPP to transition to its Grand Challenge Project focused on determining the primary function(s) of every protein itself and in networks and pathways within the context of human health and disease.

show abstract

Section: ■ Pathology Pillarmentioning

confidence: 99%

“…Proteomics has also advanced insights into COVID-19, ,, cardiovascular, , and neurological disorders, and diseases of the eye. New workflows are being developed for working with low-level ,,− and low-volume samples. , Network analysis continues to inform studies on disease-related pathways. − …”

Section: Pathology Pillarmentioning

confidence: 99%